Trademark: 77256020
Status Date
Tuesday, July 1, 2008
Filing Date
Wednesday, August 15, 2007
Abandoned Date
Monday, June 30, 2008
5 Pharmaceutical preparations, namely, oral, small-molecule, anti-copper agent that is highly specific for lowering the levels of free copper in serum; reducing toxic free copper levels and substantially improve clinical outcomes in neurologically-presenting Wilson's disease patients; treatment for fibrotic disorders, including idiopathic pulmonary fibrosis, based upon the rationale that the fibrotic disease process is dependent upon the availability of endogenous free copper; possible treatment for primary biliary cirrhosis, an autoimmune and fibrotic disease which targets the bile ducts of the liver; and treatment of other central nervous system diseases in which abnormal serum and CNS copper homeostasis are implicated, such as Alzheimer's disease
Jul 1, 2008
Abandonment Notice Mailed - Express Abandonment
Jul 1, 2008
Abandonment - Express Mailed
Jun 30, 2008
Teas Express Abandonment Received
Jun 26, 2008
Examiner's Amendment Entered
Jun 26, 2008
Notification Of Examiners Amendment E-Mailed
Jun 26, 2008
Examiners Amendment E-Mailed
Jun 26, 2008
Examiners Amendment -Written
Nov 26, 2007
Notification Of Non-Final Action E-Mailed
Nov 26, 2007
Non-Final Action E-Mailed
Nov 26, 2007
Non-Final Action Written
Nov 23, 2007
Assigned To Examiner
Aug 20, 2007
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
